

OHIP, Pharmaceuticals and
Devices Division

Delivery and Eligibility Review Branch
3rd Floor, 5700 Yonge Street
Toronto ON M2M 4K5

Telephone: (416) 327-8109
Toll Free: 1-866-811-9893
Facsimile: (416) 327-8912
Toll Free 1-866-598-6530

www.ontario.ca/health

Division de l'Assurance-santé, des produits pharmaceutiques et des
appareils et accessoires fonctionnels

Direction de la prestation des programmes et de l'examen de l'admissibilité
5700, rue Yonge, 3^e étage
Toronto ON M2M 4K5

Téléphone : (416) 327-8109
Sans frais : 1 866 811-9893
Télécopieur : (416) 327-8912
Sans frais: 1 866 598-6530

www.ontario.ca/sante

Respiratory Syncytial Virus Prophylaxis for High-Risk Infants Program

Email Address/Courriel RSVProphylaxisProgram@ontario.ca

Internet: http://www.health.gov.on.ca/en/pro/programs/drugs/funded_drug/fund_respiratory.aspx

February 16, 2022

Dear Physician/Health care practitioner:

Re: Respiratory Syncytial Virus (RSV) Prophylaxis 2021-2022 End-of-Season Date

The 2021-2022 RSV prophylaxis season will end on **February 28, 2022**.

As in previous seasons, clinics and physician offices should take inventory of their remaining stock of palivizumab vials and reduce on-hand quantities appropriately.

The goal is to deplete your palivizumab supply by the end of the season to minimize the possibility of wastage due to breaks in cold chain storage such as refrigerator malfunctions or prolonged power outages.

If dosing is required after the end date specified, the Program will consider requests on a case-by-case basis only where the local season is considered active and on-going.

The RSV season is considered on-going when there are two or more local RSV related hospitalizations per week for two consecutive weeks. The requesting physician must state the current status of the local RSV season on the submitted request. It is important that you confirm the status by contacting your local or regional hospital's infectious disease department in this regard.

Fax these case-by-case requests to the usual fax number listed on the enrolment or order form.

If you have further questions, please contact: Tamer Akkila
Senior Drugs and Therapeutics Advisor
tamer.akkila@ontario.ca

Sincerely,

(original signed by)

David Schachow
Director